CIndU Care: Antihistamine Up-Titration Anchors a Still-Gappy Algorithm
CIndU management still hinges on up-titrating H1-antihistamines up to fourfold, but experts flag thin subtype-specific evidence and a sparse pipeline beyond omalizumab.
Topic
Chronic Inducible Urticaria
Topic
Chronic Inducible Urticaria
Why Second-Generation H1 Antihistamines Fall Short in CIndU
Second-generation H1 antihistamines leave many chronic inducible urticaria patients uncontrolled, Dermatology Times review finds.
Chronic Inducible Urticaria: Epidemiology, Subtypes and QoL Burden Reviewed
Dermatology Times reviews chronic inducible urticaria epidemiology: prevalence, subtype classification, trigger-based diagnosis a…
Chronic Inducible Urticaria: The Quality-of-Life Toll Patients Carry
Patient stories collected by Dermatology Times reveal the hidden quality-of-life burden of chronic inducible urticaria, where eve…